ANVS — Annovis Bio Balance Sheet
0.000.00%
Last trade - 00:00
- $126.57m
- $123.44m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.002 | 8.07 | 45.7 | 28.4 | 5.75 |
Net Total Receivables | 0.735 | — | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.748 | 8.12 | 46 | 36 | 10.2 |
Other Long Term Assets | |||||
Total Assets | 1.12 | 8.12 | 46 | 36 | 10.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 2.01 | 0.578 | 1.51 | 7.7 | 4.28 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.62 | 0.578 | 1.51 | 7.7 | 18 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -1.5 | 7.54 | 44.5 | 28.3 | -7.75 |
Total Liabilities & Shareholders' Equity | 1.12 | 8.12 | 46 | 36 | 10.2 |
Total Common Shares Outstanding |